Efficacy of blood purification for severe pancreatitis and acute respiratory distress syndrome

Yi-hua Jin, MM*, Yang Liu, MM

Abstract
Background: This study will assess the efficacy and safety of blood purification (BP) for severe pancreatitis (SP) and acute respiratory distress syndrome (ARDS).

Methods: We will search the following electronic databases of Ovid MEDLINE, EMBASE, Web of Science, Cochrane Library, Scopus, Cumulative Index to Nursing and Allied Health Literature, the Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and WANGFANG from inception to the present without language restriction. A systematic review and data synthesis will be carried out of randomized controlled trials of BP for the treatment of patients with SP and ARDS. RevMan 5.3 software will be used for statistical analysis.

Results: This systematic review will evaluate the efficacy and safety of BP for the treatment of patients with SP and ARDS. The primary outcome includes respiratory indexes, blood biochemical and inflammatory factors. The secondary outcomes consist of complications, sepsis, abdominal hemorrhage, renal failure, length of hospital stay, and mortality.

Conclusion: This study will provide up-to-date evidence of BP for the treatment of patients with SP and ARDS.

PROSPERO registration number: PROSPERO CRD42019139467.

Abbreviations: ARDS = acute respiratory distress syndrome, BP = blood purification, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis, SP = severe pancreatitis.

Keywords: acute respiratory distress syndrome, blood purification, efficacy, randomized controlled trial, safety, severe pancreatitis

1. Introduction
Severe pancreatitis (SP) is a very common gastrointestinal disorder in clinical practice.1–3 It often results from a release of high levels of inflammatory mediators in the pancreas,4,5 and is characterized by pancreatic digestion by its own enzymes and necrosis.4,5 Such disorder often involves multiple organ dysfunction syndromes, and leads to high mortality.6–9 Additionally, SP is often complicated acute respiratory distress syndrome (ARDS),10,11 and its associated mortality rate varies from 25% to 30%.10–13 Thus, early prevention and treatment for SP are essential to enhance prognosis and the quality of life in patients with SP and ARDS.14–16

Early blood purification (BP) is very crucial and important to clear inflammatory cytokines produced at inflamed sites.17–20 In addition, this treatment can also promote the recovery of immune function and stabilizes the internal environment.19–20 Although previous studies have reported the efficacy of BP for the treatment of patients with SP and ARDS,17–20 its efficacy is still inconclusive and is not supported by the study of systematic review. Therefore, this study will systematically assess its efficacy and safety of BP for the treatment of patients with SP and ARDS.

2. Methods

2.1. Study registration
This protocol has been registered online on the PROSPERO (CRD42019139467), and it has followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Protocol statement.21

Ethics and dissemination: No research ethics approval is needed for this study, because no confidential patient data will be utilized in this systematic review. Its results will be published at a peer-reviewed journal or through conference presentations.

2.2. Study selection criteria

2.2.1. Type of studies. We will only include randomized controlled trials (RCTs) of BP for the treatment of patients with SP and ARDS. All other studies except RCTs will be excluded.
2.2.2. **Type of interventions.** Study reporting results of interventions involving BP alone for the treatment of patients with SP and ARDS will be included in the experimental group. The control treatment will include any treatments, except BP.

2.2.3. **Type of population.** We will include studies of patients with SP and ARDS regardless race, gender, and age.

2.3. **Type of outcomes**

The primary outcome includes respiratory indexes (PaO2, alveolar-arterial oxygen difference, respiratory rate, and related indexes), blood biochemical (creatinine, blood urea nitrogen, alanine aminotransferase, and lactate levels) and inflammatory (such as serum C-reactive protein, interleukin-6, and other related indexes).

The secondary outcomes consist of complications, sepsis, abdominal hemorrhage, renal failure, length of hospital stay, and mortality.

2.4. **Search strategy**

Ten electronic databases of Ovid MEDLINE, EMBASE, Web of Science, Cochrane Library, Scopus, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and WANGFANG will be searched from inception to the present without language restriction. The full search strategy for Ovid MEDLINE is available in Table 1. Similar search strategy will also be adapted to other electronic databases.

Additionally, grey literature will consist of unpublished conference proceedings or abstracts from relevant conferences, and reference lists of associated reviews.

| Number | Search terms                                           |
|--------|--------------------------------------------------------|
| 1      | Severe pancreatitis                                    |
| 2      | Pancreas inflammation                                  |
| 3      | Acute pancreatitis                                     |
| 4      | Chronic pancreatitis                                   |
| 5      | Or 1–4                                                 |
| 6      | Acute respiratory distress syndrome                    |
| 7      | ARDS                                                   |
| 8      | Wet lung                                               |
| 9      | Lung condition                                         |
| 10     | Respiratory distress syndrome, adult                   |
| 11     | Respiratory                                            |
| 12     | Distress syndrome                                      |
| 13     | Or 6–12                                                |
| 14     | Blood purification                                     |
| 15     | Blood purif                                            |
| 16     | Extracorporeal blood purification                      |
| 17     | Blood purification therapy                             |
| 18     | Or 14–17                                               |
| 19     | Randomized controlled trial                            |
| 20     | Controlled clinical trial                              |
| 21     | Random                                                 |
| 22     | Blind                                                  |
| 23     | Trials                                                 |
| 24     | Or 19–24                                               |
| 25     | 5 and 13 and 18 and 25                                  |

2.5. **Study selection process**

Two independent researchers will carry out study selection according to the pre-designed inclusion and exclusion criteria. A third researcher will solve any conflicts between two researchers through discussion. We will scan all titles and abstracts from all searched records, and we will exclude all irrelevant records. After that, all remaining studies will be read by full texts. The flowchart of study selection is exerted in Figure 1.

2.6. **Data extraction and management**

Two independent researchers will extract all relevant data based on the predefined data extraction form. Any conflicts regarding data extraction between two researchers will be solved by a third researcher via discussion. Such form contains study setting, study population, patient characteristics, diagnosis criteria, inclusion and exclusion criteria, study methods, treatment details, and outcome measurements.

2.7. **Risk of bias assessment**

Cochrane Risk of Bias Tool will be applied for risk of bias assessment for each eligible study by two independent researchers. Any discrepancies or unusual patterns will be solved by a third researcher via discussion. This tool comprises of 7 items, and each item will be assessed as 3 levels: low, unclear, and high risk of bias.

2.8. **Treatment effect measurement**

In this study, the continuous values will be calculated as mean difference or standardized mean difference and 95% confidence intervals. The dichotomous values will be calculated as risk ratio with 95% confidence intervals.

2.9. **Missing data dealing with**

We will contact primary authors from original papers if there is missing data in the eligible studies. Only available data will be analyzed if we cannot require those data.

2.10. **Heterogeneity identification**

In this study, $I^2$ test will be used to identify the heterogeneity. If the heterogeneity is less than 50%, it will be regarded as minor, and a fixed-effect model will be used. If the heterogeneity is more than 50%, it will be considered as significant and a random-effect model will be applied.

2.11. **Data synthesis**

If minor heterogeneity is identified ($I^2 \leq 50\%$), we will carry out meta-analysis when it is possible. Otherwise, if significant heterogeneity is found ($I^2 > 50\%$), we will perform subgroup analysis. If there is still significant heterogeneity after subgroup analysis, we will not conduct meta-analysis, but will only describe outcome results as narrative summary.

2.12. **Subgroup analysis**

We will carry out subgroup analysis to identify possible reasons that may cause substantial heterogeneity based on the differences of treatments, controls, and outcome assessments.
2.13. Sensitivity analysis
We will perform sensitivity analysis to explore the robustness and stability of pooled outcome results by removing low quality studies.

2.14. Publication bias
We will conduct funnel plot, Egger’s regression and Begger’s tests to check if there are any publication biases among eligible studies.

3. Discussion
Previously, no study has explored the efficacy and safety of BP for the treatment of SP and ARDS, although a variety of studies have reported its benefits for patients with SP and ARDS. This study will apply rigorous methodology to examine studies reporting the outcomes of BP for the treatment of patients with SP and ARDS. The results of study will inform our understanding of the efficacy of BP in treating SP and ARDS outcomes. The results may also provide helpful evidence for clinician and health policy-makers for treating SP and ARDS.

Acknowledgments
This study is supported by the Heilongjiang Provincial Health and Family Planning Commission Research Project (NO.2018–084). Provider did not involve all sections of this study.

Author contributions
Conceptualization: Yi-hua Jin, Yang Liu.
Data curation: Yi-hua Jin, Yang Liu.
Formal analysis: Yi-hua Jin, Yang Liu.
Funding acquisition: Yi-hua Jin.
Investigation: Yi-hua Jin.
Methodology: Yang Liu.
Project administration: Yi-hua Jin.
Resources: Yang Liu.
Software: Yang Liu.
Supervision: Yi-hua Jin.
Validation: Yi-hua Jin, Yang Liu.
Visualization: Yi-hua Jin, Yang Liu.
Writing – original draft: Yi-hua Jin, Yang Liu.
Writing – review & editing: Yi-hua Jin, Yang Liu.

References

[1] Popescu I. Management of acute severe pancreatitis. Chirurgia (Bucur) 2006;101:225–8.
[2] Ponette J, Wilmer A. Update on the management of acute severe pancreatitis. Acta Clin Belg 2001;56:135–45.
[3] Traverso LW. Infections complicating severe pancreatitis. Infect Dis Clin North Am 1992;6:601–11.
[4] Ge H, Yang G, Huang L, et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem 2004;279:2034–45.
[5] Karmik ND, Gupta AV. Predicting survival in ARDS. J Assoc Physicians India 2015;63:11–3.
[6] Bishehsari F, Sharma A, Stello K, et al. TNF-alpha gene (TNFA) variants increase risk for multi-organ dysfunction syndrome (MODS) in acute pancreatitis. Pancreatology 2012;12:113–8.
[7] Zhao W, Gong W, Yang Y. Research progress of angiogenesis like protein 2 and inflammation-related diseases. Chin J Pathophysiol 2012; 28:1986–90.
[8] Lei X, Shi F, Basu D, et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem 2011;286:15747–56.
[9] Kim I, Kim HG, Kim H, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000;346:603–10.
[10] Chacko B, Peter JV, Tharyan P, et al. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2015;1:Cd008807.
[11] Goh YY, Pal M, Chong HC, et al. Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J Biol Chem 2010;285:32999–3009.
[12] Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171–80.
[13] Valenzuela DM, Griffiths JA, Rojas J. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci US A 1999;96:1904–9.
[14] Wang ZC, Xue P, Huang ZW. Effect of an early application of Chaigvi decocation in treating severe acute pancreatitis complicated with acute respiratory distress syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009;29:322–4.
[15] Liu X, Liu Q, Pan C. Early preventive treatment for severe acute pancreatitis combined with lung injury. Chin J Traumatol 2002;5:190–2.
[16] Huang L, Zhu H, Gu J. Octreotide and continuous hemofiltration versus continuous hemofiltration alone in severe acute pancreatitis complicated with acute respiratory distress syndrome. J Coll Physicians Surg Pak 2019;29:785–7.
[17] Guo H, Suo DW, Zhu HP, et al. Early blood purification therapy of severe acute pancreatitis complicated by acute lung injury. Eur Rev Med Pharmacol Sci 2016;20:873–8.
[18] Hirasawa H. Indications for blood purification in critical care. Contrib Nephrol 2010;166:21–30.
[19] Denham W, Yang J, Wang H, et al. Inhibition of p38 mitogen activated kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome. Crit Care Med 2000;28:2567–72.
[20] Luan ZG, Zhang J, Yin XH, et al. Ethyl pyruvate significantly inhibits tumour necrosis factor-alpha, interleukin-1beta and high mobility group box 1 releasing and attenuates sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury. Clin Exp Immunol 2013;172:417–26.
[21] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[22] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[23] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.